Go Pro
→ The oil crisis is spreading faster than you think (From Golden Portfolio) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ARK Genomic Revolution ETF stock logo
ARKG
ARK Genomic Revolution ETF
$44.55
+0.5%		$38.96
$23.42
▼
$44.88
$1.99B1.622.96 million shs3.25 million shs
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$26.85
-1.6%		$30.49
$15.60
▼
$38.26
$2.82B2.231.90 million shs1.33 million shs
Alphabet Inc. stock logo
GOOGL
Alphabet
$343.80
-3.8%		$354.94
$196.60
▼
$408.61
$4.37T1.2432.69 million shs28.94 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,212.96
-1.5%		$1,165.35
$629.40
▼
$1,249.45
$1.16T0.512.79 million shs2.11 million shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$529.65
+1.1%		$478.64
$374.17
▼
$546.17
$132.97B0.31.39 million shs1.07 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ARK Genomic Revolution ETF stock logo
ARKG
ARK Genomic Revolution ETF
+0.54%+9.46%+7.82%+50.35%+90.54%
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-1.58%-5.29%-17.84%-15.70%+56.38%
Alphabet Inc. stock logo
GOOGL
Alphabet
-3.84%-8.96%-3.75%-14.61%+71.04%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-1.39%+8.72%+2.01%+19.51%+90.88%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
+1.10%+10.64%+9.12%+16.91%+41.44%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ARK Genomic Revolution ETF stock logo
ARKG
ARK Genomic Revolution ETF
$44.55
+0.5%		$38.96
$23.42
▼
$44.88
$1.99B1.622.96 million shs3.25 million shs
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$26.85
-1.6%		$30.49
$15.60
▼
$38.26
$2.82B2.231.90 million shs1.33 million shs
Alphabet Inc. stock logo
GOOGL
Alphabet
$343.80
-3.8%		$354.94
$196.60
▼
$408.61
$4.37T1.2432.69 million shs28.94 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,212.96
-1.5%		$1,165.35
$629.40
▼
$1,249.45
$1.16T0.512.79 million shs2.11 million shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$529.65
+1.1%		$478.64
$374.17
▼
$546.17
$132.97B0.31.39 million shs1.07 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ARK Genomic Revolution ETF stock logo
ARKG
ARK Genomic Revolution ETF
+0.54%+9.46%+7.82%+50.35%+90.54%
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-1.58%-5.29%-17.84%-15.70%+56.38%
Alphabet Inc. stock logo
GOOGL
Alphabet
-3.84%-8.96%-3.75%-14.61%+71.04%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-1.39%+8.72%+2.01%+19.51%+90.88%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
+1.10%+10.64%+9.12%+16.91%+41.44%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ARK Genomic Revolution ETF stock logo
ARKG
ARK Genomic Revolution ETF
2.57
Moderate Buy$44.55N/A
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
2.69
Moderate Buy$49.0082.50% Upside
Alphabet Inc. stock logo
GOOGL
Alphabet
3.04
Buy$419.8622.12% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.87
Moderate Buy$1,292.186.53% Upside
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
2.92
Moderate Buy$563.506.39% Upside

Current Analyst Ratings Breakdown

Latest GOOGL, ARKG, LLY, VRTX, and BEAM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/10/2026
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/7/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$1,376.00
8/7/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$1,370.00 ➝ $1,376.00
8/6/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$1,419.00
8/6/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$1,280.00 ➝ $1,330.00
8/6/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$1,400.00
8/6/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$1,350.00 ➝ $1,410.00
8/5/2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeBuy (B-) ➝ Buy (B)
8/5/2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$560.00 ➝ $565.00
8/5/2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$615.00 ➝ $617.00
8/4/2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$525.00 ➝ $550.00
(Data available from 8/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ARK Genomic Revolution ETF stock logo
ARKG
ARK Genomic Revolution ETF
N/AN/AN/AN/AN/AN/A
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$156.04M17.77N/AN/A$10.34 per share2.60
Alphabet Inc. stock logo
GOOGL
Alphabet
$402.84B10.44$12.19 per share28.21$50.90 per share6.75
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B17.52$24.75 per share49.01$35.99 per share33.70
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$12.00B11.20$17.77 per share29.81$79.78 per share6.64
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ARK Genomic Revolution ETF stock logo
ARKG
ARK Genomic Revolution ETF
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$79.99M-$0.86N/AN/AN/A-54.75%-30.71%-24.07%N/A
Alphabet Inc. stock logo
GOOGL
Alphabet
$132.17B$19.9117.2723.321.0054.77%51.32%35.42%10/28/2026 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$29.8040.7026.661.4533.53%97.83%23.23%10/29/2026 (Estimated)
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$3.95B$17.1830.8328.602.1735.00%23.09%16.72%N/A

Latest GOOGL, ARKG, LLY, VRTX, and BEAM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.40$8.38+$1.98$7.94$20.82 billion$22.97 billion
8/4/2026Q2 2026
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$1.11-$1.18-$0.07-$1.18$16.37 million$0.49 million
8/3/2026Q2 2026
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$4.74$4.73-$0.01$4.31$3.23 billion$3.33 billion
7/22/2026Q2 2026
Alphabet Inc. stock logo
GOOGL
Alphabet
$2.89$9.11+$6.22$9.11$117.07 billion$119.80 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ARK Genomic Revolution ETF stock logo
ARKG
ARK Genomic Revolution ETF
N/AN/AN/AN/AN/A
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$0.903.35%N/AN/A N/A
Alphabet Inc. stock logo
GOOGL
Alphabet
$0.880.26%N/A4.42%1 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.57%+15.18%23.22%11 Years
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/AN/AN/AN/AN/A

Latest GOOGL, ARKG, LLY, VRTX, and BEAM Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/22/2026
Alphabet Inc. stock logo
GOOGL
Alphabet
quarterly$0.220.28%9/4/20269/7/20269/14/2026
6/22/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.63%8/14/20268/14/20269/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ARK Genomic Revolution ETF stock logo
ARKG
ARK Genomic Revolution ETF
N/AN/AN/A
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
0.09
14.57
14.57
Alphabet Inc. stock logo
GOOGL
Alphabet
0.16
2.72
2.64
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.41
1.35
1.00
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/A
3.19
2.74

Institutional Ownership

CompanyInstitutional Ownership
ARK Genomic Revolution ETF stock logo
ARKG
ARK Genomic Revolution ETF
N/A
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
99.68%
Alphabet Inc. stock logo
GOOGL
Alphabet
40.03%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
90.96%

Insider Ownership

CompanyInsider Ownership
ARK Genomic Revolution ETF stock logo
ARKG
ARK Genomic Revolution ETF
N/A
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
3.80%
Alphabet Inc. stock logo
GOOGL
Alphabet
11.61%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
ARK Genomic Revolution ETF stock logo
ARKG
ARK Genomic Revolution ETF
N/A44.70 millionN/ANot Optionable
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
510103.29 million99.36 millionOptionable
Alphabet Inc. stock logo
GOOGL
Alphabet
190,82012.23 billion10.81 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.36 million940.04 millionOptionable
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
6,400253.80 million253.30 millionOptionable

Recent News About These Companies

One Company’s Clinical Miss Is Another’s Moat: Vertex Rallies as Sionna’s CF Bet Collapses
 |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/one-company-clinical-miss-another-034131355.html
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call
August 11 at 10:29 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/5-insightful-analyst-questions-vertex-014122962.html
4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
August 11 at 12:28 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/4-biotech-stocks-major-second-140100024.html
4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
August 11 at 11:05 AM  |  zacks.comhttps://www.zacks.com/stock/news/2972765/4-biotech-stocks-with-major-second-half-pipeline-catalysts-this-year?cid=cs-stocknewsapi-ft-analyst_blog|investment_ideas-2972765
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Handelsbanken Fonder AB
August 11 at 6:31 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-vertex-pharmaceuticals-incorporated-vrtx-shares-sold-by-handelsbanken-fonder-ab-2026-08-11/
Vertex (VRTX) Q2 2026 Earnings Call Transcript
August 11 at 1:19 AM  |  fool.comhttps://www.fool.com/earnings/call-transcripts/2026/08/10/vertex-vrtx-q2-2026-earnings-call-transcript/
Vertex Pharmaceuticals (VRTX) Is Up 5.4% After Raising 2026 Revenue Guidance And Expanding Its Pipeline - Has The Bull Case Changed?
August 10 at 8:17 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/vertex-pharmaceuticals-vrtx-5-4-151413527.html
Vertex Stock Jumps 5.9% as Rival Cystic Fibrosis Drug Fails
August 10 at 3:01 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/vertex-stock-jumps-5-9-155537840.html
Biotech Stocks To Keep An Eye On - August 10th
August 10 at 12:03 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/biotech-stocks-to-keep-an-eye-on-august-10th-2026-08-10/
Vertex Pharmaceuticals (NASDAQ:VRTX) Hits New 52-Week High - Still a Buy?
August 10 at 10:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/vertex-pharmaceuticals-nasdaqvrtx-hits-new-52-week-high-still-a-buy-2026-08-10/
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call
August 10 at 10:00 AM  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/5-insightful-analyst-questions-from-vertex-pharmaceuticals-s-q2-earnings-call/ar-AA29LcyR
Why Vertex Pharma Popped, As A Key Rival Plummeted 90%
August 10 at 10:00 AM  |  finance.yahoo.comhttps://finance.yahoo.com/m/5448cf60-d94a-347d-90d3-c5b2cd4f502f/why-vertex-pharma-popped%2C-as.html
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Beacon Investment Advisory Services Inc.
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-vertex-pharmaceuticals-incorporated-vrtx-shares-sold-by-beacon-investment-advisory-services-inc-2026-08-08/
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Q32 Bio (QTTB)
August 7, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/VRTX-Q/pressreleases/3700111/analysts-offer-insights-on-healthcare-companies-vertex-pharmaceuticals-vrtx-and-q32-bio-qttb/
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Ocular Therapeutix (OCUL) and Arcus Biosciences (RCUS)
August 7, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/VRTX-Q/pressreleases/3708949/analysts-offer-insights-on-healthcare-companies-vertex-pharmaceuticals-vrtx-ocular-therapeutix-ocul-and-arcus-biosciences-rcus/
Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire?
August 7, 2026  |  fool.comhttps://www.fool.com/investing/2026/08/07/could-1-tiny-biotech-topple-vertex-pharmaceuticals/
What Insmed Stock's Premium Is Actually Buying
August 7, 2026  |  trefis.comT
Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by Czech National Bank
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-vertex-pharmaceuticals-incorporated-vrtx-shares-purchased-by-czech-national-bank-2026-08-07/
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by PensionDanmark Pensionsforsikringsaktieselskab
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-vertex-pharmaceuticals-incorporated-vrtx-shares-acquired-by-pensiondanmark-pensionsforsikringsaktieselskab-2026-08-07/
Assenagon Asset Management S.A. Increases Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-assenagon-asset-management-sa-increases-stock-holdings-in-vertex-pharmaceuticals-incorporated-vrtx-2026-08-07/
IONQ Q2 Earnings Miss Estimates, Revenues Beat, Stock Rises
August 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/ionq-q2-earnings-miss-estimates-143900622.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Coastal oil refinery with storage tanks, a gas flare stack, and tankers anchored offshore at dusk.
As the Iran War Resumes, 2 Energy ETFs Ride Oil’s Renewed Rally
By Jessica Mitacek | July 15, 2026
Broadcom logo on a silicon wafer with circuit boards, fiber optic cables, and a network switch in a data center.
Broadcom May Be the Biggest Winner From Alphabet's Earnings
By Leo Miller | July 26, 2026
Illustration of the Google "G" logo surrounded by colorful light streaks and digital data effects.
Alphabet Crushed Earnings, But One Number Spooked the Market
By Ryan Hasson | July 23, 2026
AST SpaceMobile logo with a satellite featuring large solar arrays orbiting above Earth in space.
AST SpaceMobile’s Next Launches Could Decide Whether Its Rally Regains Orbit
By Jessica Mitacek | July 13, 2026
A JPMorgan Chase & Co. nameplate sign stands outside the company's office building at dusk.
JPMorgan’s Q2 Strength Gives the Stock Rally New Support
By Thomas Hughes | July 14, 2026
ARK Genomic Revolution ETF stock logo

ARK Genomic Revolution ETF BATS:ARKG

$44.55 +0.24 (+0.54%)
As of 08/11/2026 04:10 PM Eastern

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.

Beam Therapeutics stock logo

Beam Therapeutics NASDAQ:BEAM

$26.85 -0.43 (-1.58%)
Closing price 08/11/2026 04:00 PM Eastern
Extended Trading
$27.60 +0.75 (+2.79%)
As of 06:44 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Alphabet stock logo

Alphabet NASDAQ:GOOGL

$343.80 -13.72 (-3.84%)
Closing price 08/11/2026 04:00 PM Eastern
Extended Trading
$346.26 +2.46 (+0.72%)
As of 06:48 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alphabet Inc. offers various products and platforms in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Canada, and Latin America. It operates through Google Services, Google Cloud, and Other Bets segments. The Google Services segment provides products and services, including ads, Android, Chrome, devices, Gmail, Google Drive, Google Maps, Google Photos, Google Play, Search, and YouTube. It is also involved in the sale of apps and in-app purchases and digital content in the Google Play and YouTube; and devices, as well as in the provision of YouTube consumer subscription services. The Google Cloud segment offers infrastructure, cybersecurity, databases, analytics, AI, and other services; Google Workspace that include cloud-based communication and collaboration tools for enterprises, such as Gmail, Docs, Drive, Calendar, and Meet; and other services for enterprise customers. The Other Bets segment sells healthcare-related and internet services. The company was incorporated in 1998 and is headquartered in Mountain View, California.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,212.96 -18.98 (-1.54%)
Closing price 08/11/2026 03:59 PM Eastern
Extended Trading
$1,212.25 -0.71 (-0.06%)
As of 06:47 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Vertex Pharmaceuticals stock logo

Vertex Pharmaceuticals NASDAQ:VRTX

$529.65 +5.74 (+1.10%)
Closing price 08/11/2026 04:00 PM Eastern
Extended Trading
$528.26 -1.38 (-0.26%)
As of 06:29 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas